Boston Scientific Strengthens Board with New Leaders to Enhance Patient Care Strategy

Boston Scientific Welcomes New Leadership to Enhance Patient Care Strategy

Boston Scientific Corporation, a prominent player in the medical technology sector, fortifies its Board of Directors with the recent appointments of Cathy Smith and Christophe Weber, effective February 18, 2026. With extensive backgrounds in finance and global pharmaceutical leadership, both new board members emphasize Boston Scientific’s commitment to innovation and improving patient outcomes. Smith, the current CFO of Starbucks, boasts a strong financial strategy career, previously holding executive roles at major corporations such as Nordstrom and Walmart. Her academic credentials include an MBA from the University of Southern California and a bachelor’s degree in business economics from the University of California, Santa Barbara, shaping a vigorous approach to optimizing organizational efficiencies.

Meanwhile, Weber’s illustrious background as the president and CEO of Takeda Pharmaceutical brings invaluable pharmaceutical expertise to the board. Since joining Takeda in 2014 and assuming the CEO role in 2015, he has demonstrated a strong grasp of global market dynamics. Weber, who will retire in June 2026, has also served in senior roles at GlaxoSmithKline. His academic qualifications include a doctorate in pharmacy and an advanced degree in accounting and finance, reinforcing his strategic insight into complex healthcare environments. Mike Mahoney, Boston Scientific’s chairman and CEO, highlights that the inclusion of Smith and Weber enhances the board’s depth in leadership necessary to drive the company’s vision of disciplined growth and patient care advancements across diverse medical fields.

By integrating these seasoned professionals into its governance framework, Boston Scientific prepares to navigate an evolving healthcare landscape. The appointments come at a critical juncture, following the planned retirements of directors John Sununu and Yoshiaki Fujimori, who are stepping down at the company’s 2026 annual meeting. With more than 45 years of experience, Boston Scientific remains committed to addressing unmet medical needs across various specialties, including cardiovascular and neurological conditions. The board's new composition reflects a strategic move to leverage multifaceted expertise in improving healthcare delivery and managing costs effectively on a global scale.

In addition to its leadership changes, Boston Scientific emphasizes its mission to advance science for life by providing comprehensive device solutions tailored to complex medical challenges. As the company gears up for future developments, expectations are high for enhanced innovation that furthers its impact on patient care worldwide. The addition of Smith and Weber symbolizes a pivotal step in strengthening Boston Scientific's strategic direction and operational effectiveness in the competitive medical technology sector.